Prostaglandin E2: A putative potency indicator of the immunosuppressive activity of human mesenchymal stem cells

American Journal of Stem Cells

Volumn 1, Issue 2, 2012, Pages 138-145

  Solchaga, Luis A ^a   Zale, Elizabeth A ^b  

^a BioMimetic Therapeutics Inc   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cell culture; Cellular therapy; Immunosuppression; Mesenchymal stem cell; Prostaglandin E2

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1BETA; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; MESENCHYMAL STEM CELL; NORMAL HUMAN;

EID: 84885625516     PISSN: None     EISSN: 21604150     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
2. Maitra B, Szekely E, Gjini K, Laughlin MJ, Dennis J, Haynesworth SE and Koc ON. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004; 33: 597-604.
3. Groh ME, Maitra B, Szekely E and Koc ON. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005; 33: 928-934.
4. Auletta JJ, Deans RJ and Bartholomew AM. Emerging roles for multipotent, bone marrowderived stromal cells in host defense. Blood 2012; 119: 1801-1809.
5. Auletta JJ, Cooke KR, Solchaga LA, Deans RJ and van't Hof W. Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions. Biol Blood Marrow Transplant 2010; 16: 891-906.
6. Giordano A, Galderisi U and Marino IR. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007; 211: 27-35.
7. Uccelli A, Moretta L and Pistoia V. Immunoregulatory function of mesenchymal stem cells. European Journal of Immunology 2006; 36: 2566-2573.
8. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS and Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995; 16: 557-564.
9. Haynesworth SE, Goshima J, Goldberg VM and Caplan AI. Characterization of cells with osteogenic potential from human marrow. Bone 1992; 13: 81-88.
10. Lennon DP, Haynesworth SE, Bruder SP, Jaiswal N and Caplan AI. Human and animal mesenchymal progenitor cells from bone marrow: Identification of serum for optimal selection and proliferation. In Vitro Cellular and Developmental Biology 1996; 32: 602-611.
11. Lennon DP and Caplan AI. Isolation of human marrow-derived mesenchymal stem cells. Exp Hematol 2006; 34: 1604-1605.
12. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, Deans RJ and McIntosh KR. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005; 12: 47-57.
13. Rasmusson I, Ringden O, Sundberg B and Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76: 1208-1213.
14. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A and Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-48.
15. Auletta JJ, Zale EA, Welter JF and Solchaga LA. Fibroblast Growth Factor-2 Enhances Expansion of Human Bone Marrow-Derived Mesenchymal Stromal Cells without Diminishing Their Immunosuppressive Potential. Stem Cells Int 2011; 2011: 235176.
16. Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O and Tarkowski A. A solid-phase enzymelinked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983; 65: 109-121.
17. Zhang W, Caspell R, Karulin AY, Ahmad M, Haicheur N, Abdelsalam A, Johannesen K, Vignard V, Dudzik P, Georgakopoulou K, Mihaylova A, Silina K, Aptsiauri N, Adams V, Lehmann PV and McArdle S. ELISPOT assays provide repro-ducible results among different laboratories for T-cell immune monitoring-even in hands of ELISPOT-inexperienced investigators. J Immunotoxicol 2009; 6: 227-234.
18. Bao YS, Zhang P, Xie RJ, Wang M, Wang ZY, Zhou Z, Zhai WJ, Feng SZ and Han MZ. The regulation of CD4+ T cell immune responses toward Th2 cell development by prostaglandin E2. Int Immunopharmacol 2011; 11: 1599-1605.
19. Yanez R, Oviedo A, Aldea M, Bueren JA and Lamana ML. Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp Cell Res 2010; 316: 3109-3123.
20. Siegel G, Schafer R and Dazzi F. The immunosuppressive properties of mesenchymal stem cells. Transplantation 2009; 87: S45-49.
21. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC and Shi Y. Mesenchymal stem cellmediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-150.
22. Delarosa O, Lombardo E, Beraza A, Mancheno P, Ramirez C, Menta R, Rico L, Camarillo E, Garcia L, Abad JL, Trigueros C, Delgado M and Buscher D. Requirement of IFN-γ mediated Indoleamine 2,3 dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng Part A 2009; 15: 2795-2806.
23. Kang JW, Kang KS, Koo HC, Park JR, Choi EW and Park YH. Soluble factors-mediated immunomodulatory effects of canine adipose tissuederived mesenchymal stem cells. Stem Cells Dev 2008; 17: 681-693.
24. Rasmusson I, Ringden O, Sundberg B and Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005; 305: 33-41.